Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.00 USD
−38.37 M USD
0.00 USD
26.76 M
About Iterum Therapeutics plc
Sector
CEO
Corey N. Fishman
Headquarters
Dublin
Website
Founded
2015
ISIN
IE000TTOOBX0
FIGI
BBG00CL5KSM0
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ITRM is 1.83 USD — it has increased by 3.89% in the past 24 hours. Watch Iterum Therapeutics plc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Iterum Therapeutics plc stocks are traded under the ticker ITRM.
ITRM stock has fallen by −31.00% compared to the previous week, the month change is a 36.50% rise, over the last year Iterum Therapeutics plc has showed a 1.67% increase.
We've gathered analysts' opinions on Iterum Therapeutics plc future price: according to them, ITRM price has a max estimate of 10.00 USD and a min estimate of 5.00 USD. Watch ITRM chart and read a more detailed Iterum Therapeutics plc stock forecast: see what analysts think of Iterum Therapeutics plc and suggest that you do with its stocks.
ITRM reached its all-time high on Jun 8, 2018 with the price of 195.00 USD, and its all-time low was 0.60 USD and was reached on Dec 27, 2022. View more price dynamics on ITRM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ITRM stock is 8.29% volatile and has beta coefficient of 2.01. Track Iterum Therapeutics plc stock price on the chart and check out the list of the most volatile stocks — is Iterum Therapeutics plc there?
Today Iterum Therapeutics plc has the market capitalization of 51.45 M, it has decreased by −30.28% over the last week.
Yes, you can track Iterum Therapeutics plc financials in yearly and quarterly reports right on TradingView.
Iterum Therapeutics plc is going to release the next earnings report on Mar 31, 2025. Keep track of upcoming events with our Earnings Calendar.
ITRM earnings for the last quarter are −0.24 USD per share, whereas the estimation was −0.17 USD resulting in a −37.14% surprise. The estimated earnings for the next quarter are −0.21 USD per share. See more details about Iterum Therapeutics plc earnings.
ITRM net income for the last quarter is −6.09 M USD, while the quarter before that showed −5.00 M USD of net income which accounts for −21.95% change. Track more Iterum Therapeutics plc financial stats to get the full picture.
No, ITRM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 14.00 employees. See our rating of the largest employees — is Iterum Therapeutics plc on this list?
Like other stocks, ITRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Iterum Therapeutics plc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Iterum Therapeutics plc technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Iterum Therapeutics plc stock shows the buy signal. See more of Iterum Therapeutics plc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.